Market closed

iCAD/$ICAD

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About iCAD

icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.

Ticker

$ICAD

Sector

Health Care

Trading on

NASDAQ

Industry

Health Care Technology

Headquarters

Nashua, United States

Employees

Website

www.icadmed.com

iCAD Metrics

BasicAdvanced

$50M

-

-$0.10

1.48 -

Price and volume

Market cap

$50M

Beta

1.48

52-week high

$2.65

52-week low

$1.18

Average daily volume

224K

Financial strength

Current ratio

4.019

Quick ratio

3.727

Long term debt to equity

0.65

Total debt to equity

1.413

Interest coverage (TTM)

-437.14%

Management effectiveness

Return on assets (TTM)

-8.95%

Return on equity (TTM)

-17.56%

Valuation

Price to revenue (TTM)

2.657

Price to book

1.71

Price to tangible book (TTM)

2.41

Price to free cash flow (TTM)

-10.235

Growth

Revenue change (TTM)

10.03%

Earnings per share change (TTM)

-73.95%

3-year revenue growth (CAGR)

-19.48%

3-year earnings per share growth (CAGR)

-34.51%

What the Analysts think about iCAD

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for iCAD stock.

iCAD Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

iCAD Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

iCAD News

AllArticlesVideos

SABCS 2024: New Research Assesses iCAD's Image Based AI-Risk, Detection, and Breast Arterial Calcifications (BAC) Assessment Across Diverse Populations

GlobeNewsWire·1 month ago

CORRECTION – iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and ProFound Health Partnership with Cascaid Health at RSNA 2024

GlobeNewsWire·1 month ago

iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and a Second-Read AI Partnership with Cascaid Health at RSNA 2024

GlobeNewsWire·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ICAD

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for iCAD stock?

iCAD (ICAD) has a market cap of $50M as of January 15, 2025.

What is the P/E ratio for iCAD stock?

The price to earnings (P/E) ratio for iCAD (ICAD) stock is 0 as of January 15, 2025.

Does iCAD stock pay dividends?

No, iCAD (ICAD) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next iCAD dividend payment date?

iCAD (ICAD) stock does not pay dividends to its shareholders.

What is the beta indicator for iCAD?

iCAD (ICAD) has a beta rating of 1.48. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.